نبذة مختصرة : Idiopathic inflammatory myopathies (IIM) are complex autoimmune diseases associated with high morbidity and mortality. Although knowledge about the pathogenic mechanisms underlying IIM is improving, limited data are available to inform clinical decision-making contributing to overall poor clinical outcomes in that population. The different projects in this thesis aimed to generate knowledge to help improve clinical outcomes in IIM and covered a wide range of topics related to outcome research namely risk factors, drug effectiveness, morbidity, mortality, and healthcare costs. In study I, genetic predisposition to autoantibody development in IIM was studied using a large international cross-sectional study. Based on an unsupervised cluster analysis, eight autoantibody-defined IIM subgroups were identified, and associated with distinct HLA class II and I, supporting the incorporation of autoantibody profiles in future IIM classification projects. In study II, based on a single center experience, significant improvement in physical function was found in anti-aminoacyl tRNA synthetase (ARS) positive patients but not in anti-ARS negative patients after exposure to one cycle of rituximab. Moreover, 78% of anti-ARS positive and 50% of anti-ARS negative patients achieved moderate/major ACR/EULAR improvement, supporting the effectiveness of rituximab in IIM. In study III, using Swedish administrative databases, a 2.4-fold higher risk of acute coronary syndrome (ACS) was found in patients with IIM compared to the general population. When accounting for the competing risk of death, the cumulative incidence of ACS at 5 years was estimated at 7% in IIM compared to 3% in the general population, confirming the substantial cardiovascular burden in IIM. In study IV, a modification effect of cancer on the association between dysphagia in early disease and mortality was demonstrated using an international IIM cohort. While dysphagia exposure in the absence of cancer was not associated with higher mortality risk, exposure to ...
Relation: I. Leclair V, Galindo-Feria AS, Rothwell S, Krystufkova O, Sarrafzadeh Zargar S, Mann H, Diederichsen LP, Andersson H, Klein M, Tansley S, The DISSECT Consortium, McHugh N, Lamb J, Vencovsky J, Chinoy H, Holmqvist M, Bianchi M, Lindblad-Toh K, Padyukov L, Lundberg IE, Diaz-Gallo LM. HLA associations with autoantibody-defined subgroups in idiopathic inflammatory myopathies. [Manuscript]; II. Leclair V, Galindo-Feria AS, Dastmalchi M, Holmqvist M, Lundberg IE. Efficacy and safety of rituximab in anti-synthetase positive and negative patients – A register-based study. Rheumatology. (Oxford). 2019;58(7):1214-1220. ::doi::10.1093/rheumatology/key450 ::pmid::30690633 ::isi::000473771900015; III. Leclair V, Svensson J, Lundberg IE, Holmqvist M. Acute coronary syndrome in idiopathic inflammatory myopathies: a population-based study. Journal of Rheumatology. 2019;46(11):1509-1514. ::doi::10.3899/jrheum.181248 ::pmid::30877220 ::isi::000493976000014; IV. Leclair V, Notarnicola A, Krystufkova O, Mann H, Andersson H, Diederichsen L, Vencovsky J, Lundberg IE, Holmqvist M, Steele R, Hudson M. Effect modification of cancer on the association between dysphagia and mortality in early idiopathic inflammatory myopathies. [Manuscript]; V. Leclair V, Moshtaghi-Svensson J, Regardt M, Hudson M, Lundberg IE, Holmqvist M. Distribution and trajectory of direct and indirect costs of idiopathic inflammatory myopathies. Seminars in Arthritis and Rheumatology. 2021;51(5):983-988. ::doi::10.1016/j.semarthrit.2021.07.016 ::pmid::34407476 ::isi::000701887700013; http://hdl.handle.net/10616/48573
No Comments.